GenesisCare Launches a New Radiosurgery Center in Malaga

GenesisCare expands its business in the south of Spain. The Australian provider of radiotherapy oncology has launched the Andalusian Center of Excellence in Radiosurgery of GenesisCare Málaga, as reported by the group through a statement.

The Málaga facility aspires to become the main radiosurgery reference center in Spain to treat patients from all over Andalusia. The health complex has the first private CyberKnife S7 in Spain, an advanced equipment specialized in robotic radiosurgery.

The person in charge of leading the project at the Malaga center is Miguel Ángel Arraez, one of the most prestigious neurosurgeons in the world, who in turn collaborates with other neurosurgeons and oncologists to bring this service to patients throughout the region.

The CyberKnife S7 is a non-invasive electron linear accelerator and is intended for tumors and benign lesions anywhere in the body, including the central and peripheral nervous system (CNS), primary tumors of the lung, prostate, liver, pancreas, brain and bodily metastases.

If you want to fidn more details about GenesisCare and to find other important news in the biotech sector, download for free our companion app. The Born2Invest mobile app brings its readers the latest businews news of the day so they can stay informed.

GenesisCare has a research program with more than 150 clinical trials

The system is capable of developing a highly accurate individualized model that finds out the positional relationship between the tumor and the patient’s respiratory cycle. The model is applied during treatment so that the robot follows the movement of the tumor while it is being irradiated.

Headquartered in Sydney, Australia, GenesisCare is a global healthcare company and one of the largest integrated cancer organizations in the world. The group provides services in medical oncology, surgical oncology, radiotherapy and other therapies and has a research program with more than 150 clinical trials.

Each year, GenesisCare clinical teams care for more than 400,000 people at more than 370 cancer treatment centers, including more than 300 facilities in the United States, forty in Australia, fourteen centers in the United Kingdom and 18 sites in Spain, with more than thirty new properties under development. The organization employs more than 6,000 physicians. The Spanish subsidiary of GenesisCare closed the 2021 financial year with a turnover of €45 million and annually serves more than 8,500 patients.

In 2022, GenesisCare sold three clinics in Andalusia to the US Medical Properties Trust (MPT) in a sell and lease back operation valued at €27 million. The facilities are GenesiCare Campo de Gibraltar (Algeciras, Cádiz), GenesisCare Jerez de la Frontera (Cádiz) and Genesiscare Málaga.

__

(Featured image by Barbara-Iandolo via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.